2/21/2012 8:44:50 AM
Forest Laboratories Inc. (FRX) and Almirall SA (ALM)’s experimental drug to treat breathing complications tied to a common lung disease may be linked to higher instances of cardiovascular deaths, U.S. regulators said today. The twice-daily drug known chemically as aclidinium bromide helped patients with chronic obstructive pulmonary disease, or COPD, breathe easier, Food and Drug Administration staff said today in a report. Advisers to the agency are set to meet Feb. 23 to weigh whether safety questions concerning the medicine have been adequately assessed.
comments powered by